TMCnet News
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")REGULATED INFORMATION GHENT, Belgium, 16 January 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Marshall Wace LLP on 12 January 2018. Marshall Wace LLP notified Ablynx that as a result of an acquisition of voting securities, it has crossed the 3% threshold on 8 January 2018 and now holds 2,251,187 voting securities of Ablynx, representing 3.01% of the current 74,720,644 outstanding voting rights of Ablynx. The notification contains the following information:
The Articles of the Association of Ablynx NV provide for shareholders notification threshold of 3%, 5% or a multiple of 5% of the total number of existing voting rights. About Ablynx Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com. For more information, please contact Lies Vanneste Follow us on Twitter @AblynxABLX Ablynx media relations: Attachments: //www.globenewswire.com/NewsRoom/AttachmentNg/1a8a2c0b-2db2-4b0d-ab69-b213ad5be331 |